Indeed, recent studies demonstrate increased uptake of PSMA PET tracers by tumor tissue due to treatment with dutasteride, abiraterone, enzalutamide and ARN-509 (Meller et al. 2015; Evans et al. 2011; Kranzbühler et al. 2018, 2019; Hope et al. 2017; Lückerath et al. 2018), suggesting higher detection rates. The gene discussed is FOLH1; the disease is neoplasm.